Morningstar

Tempest Therapeutics Inc TPST

Morningstar Rating

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Sep 20, 2024 8:30pm
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

GlobeNewswire Sep 18, 2024 12:00pm
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire Sep 5, 2024 12:00pm
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Aug 23, 2024 8:30pm
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

GlobeNewswire Aug 21, 2024 12:00pm
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

GlobeNewswire Aug 15, 2024 12:00pm
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire Aug 8, 2024 8:56pm
Tempest Therapeutics shares end wild week with 8% drop

MarketWatch Oct 13, 2023 8:13pm
Tempest Therapeutics shares head back to earth after 4,000% gain

MarketWatch Oct 12, 2023 4:49pm
Tempest Therapeutics' stock jumps nearly 4,000% as liver-cancer treatment shows promise

MarketWatch Oct 11, 2023 8:04pm
Exxon Mobil, DaVita stocks drop, Novo Nordisk and Tempest Therapeutic shares rally, and other stocks on the move

MarketWatch Oct 11, 2023 2:56pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.